- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Novo Nordisk raises full-year forecast on GLP-1 drug sales
The guidance upgrade also partly reflected higher expected sales in the U.S. of its Ozempic diabetes drug, which is based on the same active ingredient as Wegovy - semaglutide.
Copenhagen: Diabetes and obesity drug developer Novo Nordisk on Thursday significantly raised its full-year operating profit and sales expectations on the back of strong demand for its highly popular Wegovy obesity drug.
"The sales outlook for 2023 is raised, primarily reflecting Wegovy prescription trends in the first quarter and higher full-year expectations for sales of Wegovy in the U.S.," Novo Nordisk said in a statement.
Novo now expects sales growth in local currencies for 2023 to come in between 24% and 30% and operating profit growth between 28% and 34%, up from a February guidance of between 13% and 19% for both those numbers.
"Novo Nordisk is a large company and growing at double-digit growth rates doesn't happen automatically. I think many other large pharmaceutical companies of Novo's caliber will be envious," Sydbank analyst Soren Lontoft Hansen told Reuters.
The guidance upgrade also partly reflected higher expected sales in the U.S. of its Ozempic diabetes drug, which is based on the same active ingredient as Wegovy - semaglutide.
Semaglutide belongs to a class of drugs known as GLP-1 analogues, which mimic an intestinal hormone which reduces appetite and increases the feeling of fullness after eating.
Novo Nordisk was overwhelmed by demand for Wegovy after it was launched in the United States in 2021 and the firm's supply constraints were exacerbated when a contract manufacturer had to temporarily suspend production over manufacturing issues.
A second contract manufacturer is ready to begin production of Wegovy, which would increase supply, Novo also said on Thursday. The company in February warned of some supply constraints this year.
"The upgrade reflects that Novo is able to meet the demand for the whole year in terms of production, because it is a very vertical curve we are seeing for Wegovy in terms of prescriptions," Hansen told Reuters.
Novo also said in March that Ozempic, its best-selling diabetes treatment drug, was back in supply after months of shortages, which could partly be explained by prescriptions to non-diabetic patients seeking to use the drug to lose weight via so-called off-label use.
Wegovy has been launched in the U.S., Denmark and Norway and the company expects the drug to be available in more European markets this year.
In the first quarter of this year, Novo's sales increased by 25% and operating profit rose by 28% in local currencies, the company said. Novo will present full financial results for the first quarter on May 4.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751